Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris

Archives of Dermatology

Volumn 144, Issue 9, 2008, Pages 1143-1147

  Firooz, Alireza ^a   Ghandi, Nargess ^b   Hallaji, Zahra ^b   Chams Davatchi, Cheyda ^b   Valikhani, Mahin ^b   Davari, Mozhgan Karbakhsh ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; PREDNISOLONE; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BLISTER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; PANCREATITIS; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; UNIVERSITY HOSPITAL;

ADULT; AZATHIOPRINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; MIDDLE AGED; PEMPHIGUS; PREDNISOLONE; TREATMENT OUTCOME;

EID: 51949101719     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.9.1143     Document Type: Article

References (21)

1. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366(9479):61-73.
2. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44(6):470-476.
3. Töth GG, Jonkman MF. Therapy of pemphigus. Clin Dermatol. 2001; 19(6):761-767.
4. EI-Azhary RA. Azathioprine: current status and future considerations. Int J Dermatol. 2003;42(5):335-341.
5. Sanderson J, Ansari A, Marinaki T. Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem. 2004;41(4):294-302.
6. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651-662.
7. Szumlanski CL. Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isoenzymes. Pharmacogenetics. 1992; 2(4):148-159.
8. Gilissen LP, Derijks LJ, Bos LP,et al. Some cases demonstrating the clinical use-fulness of therapeutic drug monitoring in thiopurine-treated Inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2004;16(7):705-710.
9. Patel AA, Swerlick RA, McCall CO. Azathioprine In dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369-389.
10. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in der-matologic patients. Arch Dermatol. 1995;131(2):193-197.
11. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol. 1995;32(1 ):114-116.
12. Anstey AV, WakelinS, Reynolds NJ; British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine In dermatology. Br J Dermatol. 2004;151 (6):1123-1132.
13. Khalil MN, Erb N, Khalil PN, Escherich G, Janka-Schaub GE. Interference free and simplified liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes [published correction appears In J Chromatogr B Analyt Technol Biomed Life Sci. 2005;824(1-2):348-350]. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;821(1):105-111.
14. Ansari A, Hassan C, Duley J.et al. Thiopurine methyltransferase activity and the use of azathioprine In inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16(10):1743-1750.
15. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in Inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther. 2002;16(3):389-398.
16. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphos-phatase 94C>A and thiopu rine S-methyl transfe rase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study [published correction appears in Clin Chem. 2006;52(8):1628]. Clin Chem. 2005;51(12):2282-2288.
17. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation [published correction appears in Liver Transpl. 2005;11 (9):1150]. Liver Transpl. 2005;11(7):826-833.
18. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with Inflammatory bowel disease. Gut. 2001;49(5):665-670.
19. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002; 51(2):143-146.
20. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147(2):308-315.
21. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies In patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005;100(10):2239-2247.